| GOLDMAN SACHS MULTI-MANAGER EMERGING MARKETS EQUITY PORTFOLIO R CAP USD | RVI EMERGENTES | 34,74% | 80,07% | 54,68% | 132,68% |
| FRANKLIN BIOTECHNOLOGY DISCOVERY A (ACC) USD | RVI BIOTECNOLOGÍA | 54,03% | 91,15% | 64,42% | 132,64% |
| SABADELL SELECCION EPSILON, FI EMPRESA | RVI GLOBAL | 19,97% | 49,03% | 55,55% | 132,63% |
| SABADELL SELECCION EPSILON, FI PLUS | RVI GLOBAL | 19,97% | 49,03% | 55,54% | 132,63% |
| FRANKLIN BIOTECHNOLOGY DISCOVERY A (ACC) HKD | RVI BIOTECNOLOGÍA | 54,00% | 91,15% | 64,45% | 132,60% |
| SCHRODER ISF GLOBAL RECOVERY B ACC USD | RVI GLOBAL | 22,69% | 49,56% | 67,90% | 132,60% |
| CAPITAL GROUP EMERGING MARKETS EQUITY FUND (LUX) Z USD | RVI EMERGENTES | 28,95% | 56,13% | 25,88% | 132,55% |
| FIDELITY FUNDS-EMERGING ASIA A-ACC-EUR | RVI ASIA EX-JAPÓN | 25,45% | 59,61% | 56,68% | 132,54% |
| INVESCO PAN EUROPEAN EQUITY C CAP EUR | RVI EUROPA | 26,86% | 46,77% | 68,78% | 132,51% |
| JUPITER ORIGIN GLOBAL EMERGING MARKETS FUND (IRL) I GBP CAP | RVI EMERGENTES | 37,94% | 68,74% | 45,28% | 132,47% |
